ESTRING (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 20h ago
ESTRING is a vaginal insert containing estradiol, an estrogen receptor agonist approved in 1996 for treating menopausal urogenital symptoms including atrophic vaginitis. The extended-release formulation delivers localized estrogen to vaginal tissues, minimizing systemic absorption while providing sustained therapeutic effect.
Product is in late-stage lifecycle with modest Part D spending (~$50M), indicating a mature, stable franchise with smaller commercial team footprint.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTRING at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moESTRING offers limited career growth potential due to its mature, stable lifecycle and approaching loss of exclusivity with zero currently linked job openings. Roles focus on defensive marketing, physician education, and market share protection rather than expansion or innovation.